Do Not Routinely Ablate Incidentally Found Angiodysplasia in Asymptomatic Patients Requiring Anticoagulation
In an asymptomatic patient requiring antiplatelet or anticoagulant therapy with incidentally discovered angiodysplasia on gastroscopy, ablation is not indicated—proceed with anticoagulation without intervention.
Clinical Reasoning
The decision hinges on balancing bleeding risk from ablation against the natural history of asymptomatic angiodysplasia:
Why Ablation is Not Recommended
Asymptomatic lesions rarely require treatment. Angiodysplasias discovered incidentally in patients without bleeding history do not mandate prophylactic ablation. The natural history shows that most remain asymptomatic, and rebleeding rates of 40-50% cited in the literature 1 apply specifically to patients who have already bled, not to incidental findings.
Ablation itself carries bleeding risk on anticoagulation. While the BSG/ESGE guidelines 2 classify diagnostic endoscopy with biopsy as low-risk (no severe hemorrhage reported in thousands of patients), therapeutic interventions like argon plasma coagulation (APC) occupy a gray zone. The guidelines acknowledge "relatively few studies of the risks of haemorrhage for endoscopic procedures in patients who continue antithrombotic therapy" 2.
Supporting Evidence for Conservative Management
Recent data from 2026 demonstrates that APC for small bowel angiodysplasia during balloon-assisted enteroscopy was performed safely without interrupting antithrombotic therapy, even in older patients with high lesion burden 3. However, this study involved symptomatic patients with capsule-confirmed bleeding—a different clinical scenario than your asymptomatic patient.
The critical distinction: These patients had established bleeding requiring intervention. Your patient has no symptoms and no indication for therapeutic endoscopy.
The Anticoagulation Decision
Proceed with anticoagulation as clinically indicated. The presence of incidental angiodysplasia should not delay or prevent necessary antiplatelet or anticoagulant therapy. The BSG/ESGE guidelines 2 emphasize that diagnostic endoscopy with biopsy can be performed safely on continued anticoagulation, with minimal bleeding risk.
A 2025 study found that 75% of angiodysplasia cases presenting with upper GI bleeding occurred in anticoagulated patients 4, but this reflects selection bias—these were patients who presented with bleeding, not incidental findings. The association does not establish causation or justify withholding necessary anticoagulation.
Practical Management Algorithm
- Document the lesion location and characteristics for future reference
- Initiate or continue anticoagulation as clinically indicated for cardiovascular/thromboembolic risk
- Counsel the patient about potential bleeding symptoms (melena, hematemesis, iron deficiency anemia)
- Monitor hemoglobin at baseline and periodically (e.g., every 6-12 months)
- Intervene only if bleeding occurs—then consider APC or other ablative therapy
Critical Caveats
Large or high-risk lesions may warrant discussion. If the angiodysplasia is unusually large (≥10mm), multiple, or in a high-risk location (e.g., actively oozing despite being "asymptomatic"), individualized assessment is reasonable. However, truly asymptomatic lesions discovered incidentally do not meet this threshold.
Avoid the temptation to "do something." The procedural risk of ablation on anticoagulation, combined with the low likelihood of future bleeding from an asymptomatic lesion, makes watchful waiting the superior strategy for morbidity and mortality outcomes.
If the patient later develops GI bleeding, the documented angiodysplasia provides a clear target for therapeutic intervention, which can be performed safely even on continued anticoagulation 3.